Group President Akdamar Erol R sold 2,900 shares of HCA at $353.00 on 2024-11-14, reducing holdings 29.8% to 6.8K shares; stock down 16.8% from 52-week high.
Akdamar Erol R sold 2,900 shares (29.8% of his pre-transaction holdings) at $353.00 on 2024-11-14, bringing his HCA position to 6.8K shares. The transaction occurred as HCA stock has declined 16.8% from its 52-week high of $415.54 and 30 days of price weakness (-13.9%). At the company level, HCA demonstrates solid fundamentals: $17.5B quarterly revenue with 7.9% annual growth and a 14.76 P/E multiple, suggesting the stock is not at distressed valuations. The insider's cross-ticker track record shows a 100.00% well-timed rate on prior sells (with -3.0% average 90-day return), and his one prior HCA sale (2023-04-28) also demonstrated well-timed exit execution (90d return -3.0%). However, this current sale occurred amid a 13.9% one-month decline and is significantly larger in percentage terms (-29.8% of holdings) than typical portfolio adjustments, warranting monitoring of near-term price stability and any related disclosure of business developments.